After a man died from excessive and irreversible bleeding after taking Dabigatran, his wife filed a lawsuit on July 12 in the U.S. District Court of Eastern Missouri (St. Louis). The plaintiff, Brenda Medley, is suing on behalf of her deceased husband, Howard Thomas Medley.

The complaint states that Medley died after suffering from severe internal bleeding while taking Pradaxa, the brand name for the medication. The plaintiff is also accusing the manufacturers of the drug, Boehringer Ingelheim, of being negligent in the marketing of the potentially deadly pills. Howard Medley first began taking Dabigatran in April 2011. He took the pills for about a year and half as part of a treatment for atrial fibrillation. By October 2012, Medley suffered from acute blood loss with iron deficiency. He died on February 22, 2013 after having blood transfusions to try to correct the bleeding.

AF is a condition that is characterized by patients suffering from fluttering and irregular heartbeats. The condition is treated with various prescription medications including anticoagulants. Dabigatran was originally marketed as a safer alternative to using Warfarin. The drug is used to help prevent strokes in AF patients, but numerous studies have revealed that Dabigatran also causes excessive and irreversible bleeding. One of the other drugs was Multaq. Multaq is made by Sanofi-Aventis and has been linked to serious side effects including a worsening of the heart condition, liver failure and lung toxicity. It is for this reason that the FDA has recommended that doctors only prescribe Multaq if all other medications fail to work.

If you or a loved one has suffered from liver failure or a worsening heart condition after being treated with Multaq, contact the attorneys at Greg Jones today for a free consultation. I am experienced at fighting Multaq lawsuits and may be able to help you recover money for your injuries.